CervoMed (NASDAQ:CRVO) announced on Tuesday that it has achieved critical regulatory and clinical alignment for the Phase 3 development of neflamapimod, its oral small-molecule treatment for dementia with Lewy bodies (DLB).
Following positive results from the Phase 2b RewinD-LB trial—which showed a statistically significant slowing of clinical progression in patients without Alzheimer’s co-pathology—the company has finalized its pivotal trial design with the FDA.
The upcoming Phase 3 trial is expected to enroll approximately 300 patients, specifically targeting those identified via pTau181 blood tests to ensure a population most likely to respond to the drug’s mechanism of action.
A key development in the company's strategy is the selection of a 50 mg three-times-daily (TID) dosing regimen using a new, stable crystal formulation.
This selection follows a year of Chemistry, Manufacturing, and Controls (CMC) work aimed at resolving batch variability issues encountered during earlier clinical phases.
By moving to this refined formulation and a slightly higher dose, CervoMed aims to consistently achieve the plasma drug concentrations that were associated with the strongest clinical benefits in the Phase 2b extension phase.
Financially, the company remains in a high-stakes position.
CervoMed reported a net loss of $27 million for the full year 2025, with R&D expenses rising to $21.8 million as it accelerated preparations for late-stage testing.
As of December 31, 2025, the company held $20.9 million in cash and equivalents, a balance that management estimates will fund operations for only about six months.